The effects of different dosage levels of hepatitis B vaccine as booster on anti-HBs-negative children 5-15 y after primary immunization; China, 2009-2010

Yongdi Chen; Huakun Lv; Hua Gu; Fujiang Cui; Fuzhen Wang; Jun Yao; Shichang Xia; Xiaofeng Liang
February 2014
Human Vaccines & Immunotherapeutics;Feb2014, Vol. 10 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • The importance of a preschool booster for children born to hepatitis B-positive mothers. Ladhani, Shamez N.; Ramsay, Mary E. // Archives of Disease in Childhood;Jun2013, Vol. 98 Issue 6, p395 

    The author focuses on the chronic hepatitis B virus (HBV) infection which is associated with cirrhosis, hapatic failure and hepatocellular carcinoma. He reports that the World Health Organization (WHO) has recommended the childhood hepatitis B immunization at birth. He mentions about the...

  • Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran. Yazdanpanah, Behrouz; Safari, Mitra; Yazdanpanah, Shahrzad // Hepatitis Monthly;Winter2010, Vol. 10 Issue 1, p17 

    Background and Aims: The duration of the protection of hepatitis B vaccination for infants and the necessity of a booster dose administration is unknown. The aim of the present study was to evaluate the persistence of seroprotection after hepatitis B virus (HBV) vaccination in order to determine...

  • Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization. Edelman, K.; Malmström, K.; He, Q.; Savolainen, J.; Terho, E. O.; Mertsola, J.; Malmström, K // European Journal of Pediatrics;1999, Vol. 158 Issue 12, p989 

    Local reactions and pertussis toxin specific immunoglobulin E antibodies (PT-IgE) were investigated in healthy children following primary and booster immunization with a combined diphtheria tetanus acellular pertussis vaccine (DTPa) including pertussis toxin, filamentous haemagglutinin and...

  • A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. Giambi, Cristina; Bella, Antonino; Barale, Antonella; Montù, Domenico; Marchisio, Maria; Oddone, Maurizio; Zito, Salvatore; Rapicetta, Maria; Chionne, Paola; Madonna, Elisabetta; Ciofi degli Atti, Marta L. // BMC Infectious Diseases;2008, Vol. 8 Issue 1, Special section p1 

    Background: In 2001, two hexavalent vaccines were licensed in Italy (Hexavac®, Infanrix Hexa®), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the market authorization of Hexavac® was precautionary...

  • Hepatitis A Vaccine. Bader, Teddy F. // American Journal of Gastroenterology;Feb1996, Vol. 91 Issue 2, p217 

    Hepatitis A continues to cause sporadic cases, epidemics, and occasional deaths in the United States. A killed virus vaccine for immunization against hepatitis A has recently been approved by the Food and Drug Administration. One hundred percent seroconversion occurs after a series consisting of...

  • The necessity of booster vaccination after neonatal hepatitis B vaccination. Lankarani, Kamran Bagheri // Hepatitis Monthly;Jun2011, Vol. 11 Issue 6, p419 

    The author reflects on the necessity to implement a boost or advancement in the vaccination for neonatal hepatitis B virus (HBV). The author states that the booster vaccination for HBV lies on impact of antibody level reduction in immunity system and on the certainty for HBV recurrence in...

  • BOOSTER SHOTS NOT NEEDED.  // AIDS Patient Care & STDs;May2000, Vol. 14 Issue 5, p285 

    Presents research findings suggesting that booster doses of hepatitis B vaccine are not needed in immunocompromised patients who respond to a primary course of immunization. Duration of protection afforded by the booster doses; Health conditions of individuals needing the booster shots.

  • Hepatitis B Immunity and Response to Booster Vaccination in Children With Inflammatory Bowel Disease Treated With Infliximab. Moses, Jonathan; Alkhouri, Naim; Shannon, Angela; Raig, Kathy; Lopez, Rocio; Danziger-Isakov, Lara; Feldstein, Ariel E; Zein, Nizar N; Wyllie, Robert; Carter-Kent, Christine // American Journal of Gastroenterology;Jan2012, Vol. 107 Issue 1, p133 

    OBJECTIVES:Hepatitis B virus (HBV) reactivation has been described in patients treated with infliximab for inflammatory bowel disease (IBD). This has resulted in a 'black box' warning. Although universal vaccination against hepatitis B was implemented in the United States in 1991, up to 10% of...

  • DTPa-HBV-IPV/Hib Vaccine (Infanrix hexaâ„¢). Curran, Monique P.; Goa, Karen L. // Drugs;2003, Vol. 63 Issue 7, p673 

    â–´ Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B recombinant (adsorbed)-inactivated poliomyelitis-adsorbed conjugated Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib; Infanrix hexaâ„¢) provided high levels of seroprotection against...

  • Vaccination and prophylaxis against hepatitis B in children.  // American Family Physician;10/1/1994, Vol. 50 Issue 5, p979 

    Discusses the prevention of hepatitis B infection in children. Immunization; Prophylaxis; Vaccine types; Schedule; Dosage and administration; Precautions; Adverse reactions.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics